Inflammatory Disease

Inflammatory Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
May 25, 2017 - N°20170145044

The invention provides compounds which are prodrugs of a jak inhibitor agent for the targeted delivery of the jak inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
NEW Rituximab induction therapy followed by glatiramer acetate therapy
May 25, 2017 - N°20170143824

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The ...
NEW Anti-inflammatory peptides and composition comprising the same
May 25, 2017 - N°20170143806

A peptide with anti-inflammatory activity, wherein the peptide comprises seq id no: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of seq id no: 1 has ...
NEW Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease
May 25, 2017 - N°20170143645

Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.
Compositions and methods for modulating myeloid derived suppressor cells
University Of South Florida
May 18, 2017 - N°20170137812

Provided are methods of treating an inflammatory disease in a subject in need thereof by administering an amount of microrna 142, an amount of microrna 223 or an amount of microrna 142 and an amount of micro rna 223 to the subject in need thereof.
Cd3-binding molecules capable of binding to human and non-human cd3
Macrogenics, Inc.
May 18, 2017 - N°20170137519

The present invention relates to cd3-binding molecules capable of binding to human and non-human cd3, and in particular to such molecules that are cross-reactive with cd3 of a non-human mammal (e. G., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other ...
Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aryl sultam derivatives as rorc modulators
Macrogenics, Inc.
May 18, 2017 - N°20170137393

Or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, x1, x2, x3, x4, y, z, a, r1, r2, r3, r4, r5 r6, r7, r8, r9, r10, r11, r12 and r13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.
Composition for treating ischemic diseases or neuroinflammatory diseases containing neural progenitor cells or secretome thereof ...
Industry-academic Cooperation Foundation, Yonsei University
May 18, 2017 - N°20170136068

The present invention provides a composition for treating ischemic diseases or neuroinflammatory diseases. Psa-ncam-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The psa-ncam-positive neural progenitor cells can be simply isolated by using an anti-psa-ncam-antibody, and exhibit excellent angiogenic and anti-inflammatory activities compared with mesenchymal stem cells, and thus can ...
Corticosteroids for the treatment of joint pain
Flexion Therapeutics, Inc.
May 18, 2017 - N°20170135957

Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a ...
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or ...
Prothena Biosciences Limited
May 11, 2017 - N°20170129954

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory ...
Urea derivatives and uses thereof
Kala Pharmaceuticals, Inc.
May 11, 2017 - N°20170129876

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e. G., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or ...
Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
E&b Technologies Llc
May 11, 2017 - N°20170128520

Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.
Method of isolating sphingolipids from cordyceps and their use
Macau University Of Science And Technology
May 11, 2017 - N°20170128507

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from cordyceps, in particular from wild-type cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not ...
Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
4-alkynyl imidazole derivative and medicine comprising same as active ingredient
Kaken Pharmaceutical Co., Ltd.
May 11, 2017 - N°20170128431

There are provided 4-alkynylimidazole derivatives represented by the following general formula (i) or pharmaceutically acceptable salts thereof; the derivatives have a superior ep4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the ep4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, ...
Mesenchymal stem cell-derived exosomes and their uses
Tigenix S.a.u.
May 04, 2017 - N°20170121685

The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups
Tigenix S.a.u.
May 04, 2017 - N°20170121322

Furthermore, this invention relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
The Johns Hopkins University
May 04, 2017 - N°20170119897

A dendrimer formulation, such as a pamam dendrimer or a multiarm peg polymeric formulation has been developed for oral administration to the gastrointestinal tract for treatment of inflammatory diseases associated with infection or cancer. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine) (pamam) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, ...
Lanthionine synthetase c-like 2-based therapeutics
Biotherapeutics, Inc.
May 04, 2017 - N°20170119762

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
Chiesi Farmaceutici S.p.a.
May 04, 2017 - N°20170119753

Compounds of formula i, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
Mesenchymal stem cell-derived exosomes and their uses
Tigenix, S.a.u.
May 04, 2017 - N°20170119682

The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
Specific modulators of connexin hemichannels
Tigenix, S.a.u.
April 27, 2017 - N°20170115276

In particular, the invention provides compounds specifically inhibiting the activation/opening of connexin hemichannels identified through the method described above, which can be useful for the treatment of inflammatory diseases, vascular disorders, arrhythmias, chronic injuries, retinal neuroprotection, treatment of pain, skeletal muscle denervation, muscular dystrophies, damage to the spinal cord and genetic diseases characterized by the increased activity of hemichannels ...